

REMARKS

Any fees that may be due in connection with the filing of this paper or with this application may be charged to Deposit Account No. 06-1050. If a Petition for Extension of time is needed, this paper is to be considered such Petition.

The specification is amended to correct obvious typographical, spelling, and grammatical errors. Additionally, the specification is amended at paragraph [094] on page 18 to correct a spelling error by replacing "sale" with -salt-. The basis for this amendment is found throughout the specification, for example, on page 26, lines 21-22 which correctly recites "...or a pharmaceutically acceptable salt, ester...".

The amendment at page 25, lines 23-24 seeks to correct the name of Compound 178 by replacing "methyl" with -ethyl-. The basis for this amendment is found on page 68, paragraph [0307] which defines the R⁷ group of Compound 178 as hydroxymethyl. The hydroxymethyl group adds a second carbon to the substituent at the second position of the piperidinyl ring and necessitates the use of "ethyl" as the substituent's base name. Further basis for this amendment is found in Scheme I on page 31, line 1 which correctly displays Compound 178 as Structure 10. Likewise, the name of Compound 178 is also corrected at page 68, paragraph [0307].

The amendment at page 26, lines 11-14 seeks to correct the names of Compound 187 and Compound 188 by replacing "Hydroxyethyl" with -(2-Hydroxyethyl)-. The basis for this amendment is found on page 71, paragraph [0324] which defines the R⁹ group as hydroxymethyl for Compounds 187 and 188. The hydroxymethyl group places a hydroxy moiety on the second carbon of the substituent at the second position of the pyrrolidinyl ring. This necessitates the designation of "2-Hydroxyethyl" to correctly name the substituent. Further basis for this amendment is found in Scheme I on page 31, line 1 which correctly displays Compound 187 and Compound 188 as Structure 10. Likewise, the names of Compound 187 and Compound 188 are corrected at page 71, paragraph [0324]. The amendment at page 71, paragraph [0324] also seeks to correct the R group designations of Compound 188 (Structure 10 of Scheme I) by switching the R³ and R⁴ groups. The basis for this amendment is found on page 71, paragraph [0324] which names Compound 188 as "5(*S*)-methyl". The "*S*" stereodescriptor designates the R⁴ group at the fifth position of the pyrrolidinyl ring as methyl instead of as hydrogen. The "*S*" stereodescriptor also designates the R³ group at the fifth position of the pyrrolidinyl ring as hydrogen instead of as methyl. Therefore, the R³ and R⁴ groups of Compound 188 should be switched.

The amendment at page 69, paragraph [0313] seeks to correct the R⁹ groups of Compounds 181, 182, and 183 (Structure 10 of Scheme I) by replacing “chloro” with “hydroxy”. The basis for this amendment is found on page 69, paragraph [0313] which correctly names Compounds 181, 182, and 183 with hydroxy substituents on the first carbon at the second position of the pyrrolidinyl ring. This position corresponds to the R⁹ group of Structure 10 of Scheme I as displayed on page 31, line 1 and should be designated as “hydroxy” instead of “chloro”.

The amendment at page 70, paragraph [0322] seeks to correct the R⁹ group of Compound 186 (Structure 10 of Scheme I) by replacing “acetyloxymethyl” with “acetyloxy”. The basis for this amendment is found on page 70, paragraph [0322] which correctly names Compound 186 with an acetyloxymethyl substituent at the second position of the piperidinyl ring. This corresponds to the R⁹ group of Structure 10 of Scheme I as displayed on page 31, line 1 and should be designated as “acetyloxy” instead of “acetyloxymethyl”.

The amendment at page 76, paragraph [0345] seeks to correct a mathematical error by replacing “350” with “360”. The basis for this amendment is found in the table on page 76, paragraph [0345] which displays the quantities of ingredients in column 2. The summation of these quantities yields 360 instead of 350.

The amendment at page 78, paragraph [0349] seeks to correct the error in total volume of the formulation by replacing “100” with “1,000”. The basis for this amendment is found in the instant paragraph which presents the volume of saturated fatty acid glycerides (1,000 mL) used to dissolve Compound 145. In this instance, the volume of a single component can not be less than the total volume of the entire formulation. Therefore, the total volume is equal to the volume of the saturated fatty acid glycerides used to dissolve Compound 145, which is 1,000 mL.

Claims 1-44 are pending. Claims 13 and 22 are amended herein. Claim 13 is amended to correct the name of Compound 178 by replacing “methyl” with “ethyl”. The basis for this amendment is found on page 68, paragraph [0307] which defines the R⁷ group of Compound 178 as hydroxymethyl. The hydroxymethyl group adds a second carbon to the substituent at the second position of the piperidinyl ring and necessitates the use of “ethyl” as the substituent's base name. Further basis for this amendment is found in Scheme I on page 31, line 1 which correctly displays Compound 178 as Structure 10. Likewise, Claim 22 is also amended to correct the name of Compound 178 by replacing “methyl” with “ethyl”.


Claim 13 is also amended to correct the names of Compound 187 and Compound 188 by replacing "Hydroxyethyl" with -(2-Hydroxyethyl)-. The basis for this amendment is found on page 71, paragraph [0324] which defines the R⁹ group of Compound 187 and Compound 188 as hydroxymethyl. The hydroxymethyl group designates a hydroxy moiety on the second carbon of the substituent at the second position of the pyrrolidinyl ring. This necessitates the designation of "2-Hydroxyethyl" to correctly name the substituent. Further basis for this amendment is found in Scheme I on page 31, line 1 which correctly displays Compound 187 and Compound 188 as Structure 10. Likewise, Claim 22 is also amended to correct the name of Compound 187 and Compound 188 by replacing "Hydroxyethyl" with -(2-Hydroxyethyl)-.

Accordingly, no new matter has been added to the specification or to the claims.

* * *

Entry of this amendment and examination of the application are respectfully requested.

Respectfully submitted,



Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 18202-030US1 / 1111US

Address all correspondence to:

Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com

10672772.doc